Cardioprotective effect of carvedilol: Inhibition of apoptosis in H9c2 cardiomyocytes via the TLR4/NF-κB pathway following ischemia/reperfusion injury

Experimental and Therapeutic Medicine

Volumn 8, Issue 4, 2014, Pages 1092-1096

  Zhao, Yong ^a   Xu, Yan ^a   Zhang, Jianhua ^a   Ji, Tingting ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Carvedilol; H9c2; Ischemia reperfusion; Toll like receptor 4 nuclear factor light chain enhancer of activated B cells

Indexed keywords

CARVEDILOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PYRROLIDINE DITHIOCARBAMATE; TOLL LIKE RECEPTOR 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; DENSITOMETRY; FLOW CYTOMETRY; GENE EXPRESSION; HEART PROTECTION; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; RAT; REOXYGENATION; REPERFUSION INJURY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84906506109     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1863     Document Type: Article

References (22)

1. Jayachandran M, Brunn GJ, Karnicki K, Miller RS, Owen WG and Miller VM: In vivo effects of lipopolysaccharide and TLR4 on platelet production and activity: implications for thrombotic risk. J Appl Physiol (1985) 102: 429-433, 2007.
2. Zhong X, Li X, Qian L, et al: Glycine attenuates myocardial ischemia-reperfusion injury by inhibiting myocardial apoptosis in rats. J Biomed Res 26: 346-354, 2012.
3. Lin J, Wang H, Li J, et al: κ-Opioid receptor stimulation modulates TLR4/NF-κB signaling in the rat heart subjected to ischemia-reperfusion. Cytokine 61: 842-848, 2013.
4. Kim SC, Stice JP, Chen L, et al: Extracellular heat shock protein 60, cardiac myocytes, and apoptosis. Circ Res 105: 1186-1195, 2009.
5. Zhao P, Wang J, He L, et al: Deficiency in TLR4 signal transduction ameliorates cardiac injury and cardiomyocyte contractile dysfunction during ischemia. J Cell Mol Med 13: 1513-1525, 2009.
6. Riad A, Jäger S, Sobirey M, et al: Toll-like receptor-4 modulates survival by induction of left ventricular remodeling after myocardial infarction in mice. J Immunol 180: 6954-6961, 2008.
7. Leonetti G and Egan CG: Use of carvedilol in hypertension: an update. Vasc Health Risk Manag 8: 307-322, 2012.
8. Kanoupakis EM, Manios EG, Mavrakis HE, et al: Electrophysiological effects of carvedilol administration in patients with dilated cardiomyopathy. Cardiovasc Drugs Ther 22: 169-176, 2008.
9. Le DE, Pascotto M, Leong-Poi H, Sari I, Micari A and Kaul S: Anti-inflammatory and pro-angiogenic effects of beta blockers in a canine model of chronic ischemic cardiomyopathy: comparison between carvedilol and metoprolol. Basic Res Cardiol 108: 384, 2013.
10. Mori Y, Nishikawa Y, Kobayashi F and Hiramatsu K: Clinical status and outcome of Japanese heart failure patients with reduced or preserved ejection fraction treated with carvedilol. Int Heart J 54: 15-22, 2013.
11. Chen-Scarabelli C, Saravolatz L Jr, Murad Y, et al: A critical review of the use of carvedilol in ischemic heart disease. Am J Cardiovasc Drugs 12: 391-401, 2012.
12. Liu Q, Zhang J, Xu Y, Huang Y and Wu C: Effect of carvedilol on cardiomyocyte apoptosis in a rat model of myocardial infarction: a role for toll-like receptor 4. Indian J Pharmacol 45: 458-463, 2013.
13. Esumi K, Nishida M, Shaw D, Smith TW and Marsh JD: NADH measurements in adult rat myocytes during simulated ischemia. Am J Physiol 260: H1743-1752, 1991.
14. Dargie HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357: 1385-1390, 2001.
15. Jin YC, Kim CW, Kim YM, et al: Cryptotanshinone, a lipophilic compound of Salvia miltiorrriza root, inhibits TNF-alpha-induced expression of adhesion molecules in HUVEC and attenuates rat myocardial ischemia/reperfusion injury in vivo. Eur J Pharmacol 614: 91-97, 2009.
16. Lin E, Freedman JE and Beaulieu LM: Innate immunity and toll-like receptor antagonists: a potential role in the treatment of cardiovascular diseases. Cardiovasc Ther 27: 117-123, 2009.
17. Ishikawa Y, Satoh M, Itoh T, Minami Y, Takahashi Y and Akamura M: Local expression of Toll-like receptor 4 at the site of ruptured plaques in patients with acute myocardial infarction. Clin Sci (Lond) 115: 133-140, 2008.
18. Poole-Wilson PA, Swedberg K, Cleland JG, et al; Carvedilol Or Metoprolol European Trial Investigators: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362: 7-13, 2003.
19. Fiuzat M, Wojdyla D, Kitzman D, et al: Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial. J Am Coll Cardiol 60: 208-215, 2012.
20. Soriano ME and Scorrano L: Traveling Bax and forth from mitochondria to control apoptosis. Cell 145: 15-17, 2011.
21. Condorelli G, Morisco C, Stassi G, et al: Increased cardiomyocyte apoptosis and changes in proapoptotic and antiapoptotic genes bax and bcl-2 during left ventricular adaptations to chronic pressure overload in the rat. Circulation 99: 3071-3078, 1999.
22. Shimamoto A, Chong AJ, Yada M, et al: Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation 114 (1 Suppl): I270-I274, 2006.